more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 22,2019

While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.

biotechs

Will Bristol-Myers (BMY) Disappoint This Earnings Season?

by Zacks Equity Research Published on April 22,2019

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.

pharmaceuticals

Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

by Zacks Equity Research Published on April 18,2019

Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

pharmaceuticals

Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on April 17,2019

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIIBNegative Net Change

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on April 15,2019

Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.

BIIBNegative Net Change

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on April 09,2019

Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.

BIIBNegative Net Change

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research Published on April 02,2019

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BIIBNegative Net Change

Celgene Gets Positive CHMP Nod for Revlimid Label Expansion

by Zacks Equity Research Published on April 01,2019

Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.

biotechs

Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

by Zacks Equity Research Published on April 01,2019

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

pharmaceuticals

4 Small Biotech Stocks Likely to Witness More Upside in 2019

by Zacks Equity Research Published on March 29,2019

The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

biotechs

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

by Zacks Equity Research Published on March 27,2019

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

pharmaceuticals

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

by Zacks Equity Research Published on March 27,2019

Key highlights of the past week are multiple study failures and other pipeline updates.

biotechs

Celgene (CELG) Submits NDA for MS Drug to FDA for Review

by Zacks Equity Research Published on March 26,2019

Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

biotechs

AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan

by Zacks Equity Research Published on March 26,2019

AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

pharmaceuticals

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research Published on March 22,2019

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

biotechs

Company News For Mar 22, 2019

by Zacks Equity Research Published on March 22,2019

Companies in the news are: BIIB, CAG, DRI, WSM

Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets

by Mark Vickery Published on March 21,2019

Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.

Initial Jobless Claims Decline

by Zacks Equity Research Published on March 21,2019

Initial Jobless Claims Decline

BIIBNegative Net Change

medical

Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets

by Mark Vickery Published on March 21,2019

Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.